Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)

A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (DREAMM 4)

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03848845

Acronym

DREAMM 4

Enrollment

Registered

2019-02-21

Start date

2019-03-14

Completion date

2023-06-14

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

GSK2857916, Pembrolizumab, Multiple Myeloma, RP2D

Brief summary

This is a phase I/II, single arm, open label, two-part study that will assess safety, tolerability and clinical activity of GSK2857916 given in combination with a programmed cell death-1 (PD-1) inhibitor pembrolizumab in subjects with RRMM. This study will enroll adult subjects with RRMM, who have undergone stem cell transplant or who are considered transplant ineligible. Part 1 is a dose escalation phase to evaluate the safety and tolerability of escalating doses of GSK2857916 in combination with 200 milligrams (mg) pembrolizumab to establish the recommended phase 2 dose (RP2D). The following dose levels of GSK2857916 are planned to be studied: 2.5 milligrams per kilograms (mg/kg) (dose level \[DL\] 1) and 3.4 mg/kg (DL2). Part 2 is a dose expansion cohort. Once the RP2D has been identified, an expansion cohort will open for enrolment to confirm the safety profile and to evaluate the clinical activity of the combination. Up to 40 evaluable subjects will be enrolled in this two-part study (up to 12 in Part 1, and 28 in Part 2).

Interventions

DRUGbelantamab mafodotin

belantamab mafodotin will be available as 20 milligrams per millilitre (mg/mL) solution for IV infusion, supplied as frozen liquid. belantamab mafodotin solution will be diluted in normal 0.9% saline to the appropriate concentration for the dose.

DRUGPembrolizumab

Pembrolizumab will be available as 100 mg/4 mL solution that should be stored under refrigeration at 2-8 degree Celsius. Pembrolizumab injection (solution) will be diluted prior to IV administration in 0.9% sodium chloride injection or 5% dextrose injection.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Masking

NONE

Masking description

This will be an open-label study. Hence, there will be no masking.

Intervention model description

Subjects will receive GSK2857916 at escalating doses along with pembrolizumab on Day 1 of each 21-day Cycle to establish RP2D during the Part 1 of the study. Subjects will receive GSK2857916 at RP2D along with pembrolizumab on Day 1 of each 21-day Cycle in Part 2 of the study.

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Provide signed written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. * Male or female, 18 years or older (at the time consent is obtained). * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Subjects must: have histologically or cytologically confirmed diagnosis of Multiple myeloma (MM), as defined by IMWG, 2014 and has undergone stem cell transplant or is considered transplant ineligible, and has been treated with at least 3 prior lines of prior anti-myeloma treatments including an immunomodulatory imide drug (IMiD) (eg. lenalidomide or pomalidomide), a proteasome inhibitor (eg. bortezomib, ixazomib or carfilzomib) and an anti-CD38 antibody alone or in combination. Line of therapy are defined by consensus panel of the International Myeloma Workshop, Has measurable disease defined as one the following: a) Serum M-protein \>=0.5 grams per deciliter (g/dL) (\>=5 grams per liter \[g/L\]). b) Urine M-protein ≥200 mg/24h. c) Serum Free light chain (FLC) assay: Involved FLC level ≥10 milligrams per deciliter (mg/dL) (≥100 milligrams per liter \[mg/L\]) and an abnormal serum free light chain ratio (\<0.26 or \>1.65). * Subjects with a history of autologous stem cell transplant are eligible for study participation provided the following eligibility criteria are met: a) transplant was \> 100 days prior to study enrolment. b) no active infection(s). c) subject meets the remainder of the eligibility criteria. * Adequate organ system functions as defined by the laboratory assessments. * All prior treatment-related toxicities (defined by National Cancer Institute-Common Toxicity Criteria for Adverse Events \[NCI-CTCAE\], version 4.03, 2010) must be \<= Grade 1 at the time of enrolment except for alopecia and Grade 2 neuropathy. * A female subject is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of childbearing potential (WOCBP) OR is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), preferably with low user dependency, during the intervention period and for at least 120 days after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention. A WOCBP must have a negative highly sensitive serum pregnancy test (as required by local regulations) within 72 hours before the first dose of study intervention. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy. * Male subjects are eligible to participate if they agree to the following during the intervention period and for at least 140 days after the last dose of study intervention. Male subjects should refrain from donating sperm, plus, either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR Must agree to use a male condom and female partner to use an additional highly effective contraceptive method with a failure rate of \<1% per year when having sexual intercourse with a woman of childbearing potential who is not currently pregnant.

Exclusion criteria

A subject will NOT be eligible for inclusion in this study if any of the following criteria apply: * Systemic anti-myeloma therapy or an investigational drug \<=14 days or five half-lives, whichever is shorter, preceding the first dose of study drug * Plasmapheresis within 7 days prior to the first dose of study drug * Prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drugs * Has received prior therapy with an anti-PD-1, anti-Programmed cell death Ligand 1 (PD-L1), or anti-Programmed cell death Ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated antigen 4 \[CTLA-4\], OX 40, CD137) and was discontinued from that treatment due to a Grade 3 or higher immune related adverse event (irAE) * Current corneal epithelial disease except mild punctate keratopathy * Any major surgery within the last four weeks prior to the first dose of study therapy * Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect subject's safety). Subjects with isolated proteinuria resulting from MM are eligible, provided they fulfil criteria as per adequate organ system function mentioned under inclusion criteria. * Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures. * Has received prior radiotherapy within 2 weeks of start of study therapy. Subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (\<=2 weeks of radiotherapy) to non-central nervous system (CNS) disease. * History of (non-infectious) pneumonitis that required steroids, or current pneumonitis * Current active liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. * Malignancies other than disease under study are excluded, except for any other malignancy from which the subject has been disease-free for more than 2 years and, in the opinion of the principal investigators and GSK Medical Monitor, will not affect the evaluation of the effects of this clinical trial treatment on the currently targeted malignancy (RRMM). Subjects with curatively treated non-melanoma skin cancer are allowed. * Has known active CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study therapy * Evidence of cardiovascular risk including any of the following: a) corrected for heart rate by Fridericia's formula (QTcF) interval ≥470 msecs. b) Evidence of current clinically significant uncontrolled arrhythmias; i. including clinically significant ECG abnormalities including 2nd degree (Type II) or 3rd degree atrioventricular (AV) block. c) History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within six months of Screening. d) Class III or IV heart failure as defined by the New York Heart Association functional classification system. e) Uncontrolled hypertension. f) Presence of cardiac pacemaker (or defibrillator) with a predominantly ventricular paced rhythm, limiting ECG/QTcF analysis. g) Abnormal cardiac valve morphology (\>=Grade 2) documented by echocardiogram (subjects with grade 1 abnormalities \[i.e., mild regurgitation/stenosis\] can be entered on study). Subjects with moderate valvular thickening should not be entered on study. * Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK2857916 or pembrolizumab, or any of the components of the study treatment. * Pregnant or lactating female. * Known active infection requiring antibiotic, antiviral, or antifungal treatment. * Known Human Immunodeficiency Virus (HIV) infection. * Presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study treatment * Positive hepatitis C antibody test result or positive hepatitis C Ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study treatment. * Has received a live-virus vaccination within 30 days of planned start of study therapy. * Active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other chronic form of immunosuppressive therapy within 7 days prior the first dose of study therapy. * Has known psychiatric or substance abuse disorder that would interfere with the subject's ability to cooperate with the requirements of the study. * Has had an allogenic tissue/solid organ transplant

Design outcomes

Primary

Measure	Time frame	Description
Part 1 - Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	Up to approximately 31 months	An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function.
Part 1 - Number of Participants With Dose Limiting Toxicities (DLTs)	Up to 21 days	DLT is an AE that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 21 day DLT period and meets at least one of the DLT criteria: any Grade 4 and 3 non-hematologic toxicity, any Grade 3 or greater non-hematologic laboratory value, hematologic toxicity lasting \>=7 days, except Grade 4 thrombocytopenia of any duration or Grade 3 thrombocytopenia associated with clinically significant bleeding. Grade 3 or greater febrile neutropenia lasting \>48 hours (h) despite adequate treatment, Nephrotoxicity requiring dialysis, Liver toxicity, prolonged delay (\>14 days) in initiating Cycle 2 due to any treatment (pembrolizumab or GSK2857916) related toxicity, any treatment-related toxicity that causes discontinuation of treatment during Cycle 1, any other toxicity considered to be dose-limiting that occurs beyond 21 days and any other event which in the judgment of the investigator and GlaxoSmithKline Medical Monitor is considered to be a DLT.
Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Baseline (Day 1) and up to approximately 31 months	Blood samples were collected for the analysis of following hematology parameters: hemoglobin, White blood cells (WBC) count, lymphocytes, neutrophils and platelet count. The laboratory parameters were graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Any worst-case post baseline increase in grade along with any increase to a maximum grade of 3 and a maximum grade of 4 are presented.
Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Baseline (Day 1) and up to approximately 31 months	Blood samples were collected for the analysis of following hematology parameters: basophils, eosinophils, mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), erythrocytes, hematocrit, monocytes, neutrophils and reticulocyte. The summaries of worst-case change from baseline with respect to normal range was analyzed for only those laboratory tests that were not gradable by CTCAE version 4.03. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented.
Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Baseline (Day 1) and up to approximately 31 months	Blood samples were collected for the analysis of clinical chemistry parameters: glucose, alanine aminotransferase (ALT), albumin, alkaline phosphatase, aspartate aminotransferase (AST), blood bilirubin, calcium, creatine kinase (CPK), creatinine, gamma glutamyl transferase (GGT), magnesium, phosphate, potassium and sodium. Laboratory parameters were graded according to NCI-CTCAE version 4.03. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Any worst case post baseline increase in grade along with any increase to a maximum grade of 3 and a maximum grade of 4 are presented.
Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Baseline (Day 1) and up to 31 months	Blood samples were collected for the analysis of following chemistry parameters: calcium, carbon dioxide, chloride, direct bilirubin, protein, thyrotropin (TSH), thyroxine (T4) and triiodothyronine (T3). The summaries of worst case change from baseline with respect to normal range was analyzed for only those laboratory tests that were not gradable by CTCAE version 4.03. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented.
Part 1 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Baseline (Day 1) and up to approximately 31 months	Urine samples were collected to assess urine glucose, protein, occult blood and ketones using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase. Data for worst-case post baseline urinalysis results is presented.
Part 1 - Changes From Baseline in Urine Potential of Hydrogen (pH)	Baseline (Day 1) and Week 46	Urine samples were collected from participants to assess urine pH levels. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.
Part 1 - Changes From Baseline in Urine Specific Gravity	Baseline (Day 1) and Week 46	Urine samples were collected from participants to assess urine specific gravity. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.
Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)	Baseline (Day 1) and up to approximately 31 months	DBP and SBP were measured after resting for at least 5 minutes in a supine or semi-recumbent position. They were graded according to NCI-CTCAE version 4.03. For SBP: Grade 0 (\<=120 millimeter of mercury \[mmHg\]), Grade 1 (121-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (\>=160 mmHg). For DBP: Grade 0 (\<=80 mmHg), Grade 1 (81-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (\>=100 mmHg). Higher grade indicates greater severity. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post baseline with any grade increase and a maximum post-baseline grade increase to Grade 3 from their baseline grade are presented.
Part 1 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature	Baseline (Day 1) and up to approximately 31 months	Vital signs (pulse rate and temperature) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. The abnormal vital sign ranges were: For pulse rate (low \<60 beats per minute \[bpm\] and high \>100 bpm); For body temperature (\<=35 degrees Celsius or \>=38 degrees Celsius). Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case change from baseline was presented as Baseline to low, Baseline to Normal or No change and Baseline to High.
Part 2 - Percentage of Participants With Overall Response Rate (ORR)	Up to approximately 31 months	ORR was defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response \[VGPR\], complete response \[CR\] and stringent complete response \[sCR\]), according to the International Myeloma Working Group (IMWG) Response Criteria. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h; PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h.

Secondary

Measure	Time frame	Description
Part 2 - Time Taken for the Onset of First Occurrence of Worsening in BCVA Score	Up to approximately 178 weeks	The time for the onset of any visual acuity event (change from baseline logMAR score \>= 0.3 in either eye) was calculated.
Part 2 - Outcome of First Occurrence of Worsening Eye in BCVA Score	Up to approximately 178 weeks	The onset of any visual acuity event (change from baseline in logMAR score \>= 0.3 in either eye) was considered resolved if the change from baseline in logMAR score was less than 0.3 in both eyes. Participants with resolved and not resolved outcome of the worsening eye were presented.
Part 2 - Duration of First Occurrence of Worsening in BCVA Score	Up to approximately 178 weeks	The time from onset of any visual acuity event (change from baseline logMAR score \>= 0.3 in either eye) until the event is resolved (change from baseline logMAR score \< 0.3 in both eyes) was used to calculate the duration of first occurrence.
Part 2 - Number of Participants According to the Number of Definite Events of Worsening of Vision	Up to approximately 178 weeks	A definite worsened vision was defined as a change from baseline \>=0.3 logMAR score.
Part 2 - Number of Participants With Resolution of Post Treatment Exposure Worsening in BCVA Score	Up to approximately 178 weeks	The event was considered resolved if the change from baseline in logMAR score \< 0.3 in both eyes.
Part 2 - Duration of Resolution Post-treatment Exposure of Worsening in BCVA Score	Up to approximately 178 weeks	The time taken for the resolution of worsening eye post treatment exposure. Duration was defined as the time from onset of any visual acuity event (change from baseline logMAR score \>= 0.3 in either eye) until the event was considered resolved (change from baseline logMAR score \< 0.3 in both eyes). It required at least a one day gap between the resolution of all events from first occurrence to the onset of second occurrence. The end of treatment exposure was defined as 20 days from last infusion date.
Part 2 - Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception	Baseline (Day 1) and up to approximately 178 weeks	—
Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam	Baseline (Day 1) and up to approximately 178 weeks	Participants with worst-case shift from baseline in corneal epithelium defects by right eye, left eye and worse eye are presented as normal (N), abnormal (AN) and missing. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.
Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Baseline (Day 1) and up to approximately 178 weeks	Participants with worst-case shift from baseline in corneal examination: corneal ulcer, epithelial microcystic edema, subepithelial haze, corneal neovascularization and microcysts without edema, by right eye (R), left eye (L) and worse eye (W) are presented as yes (Y), no (N) and missing (M). Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.
Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Baseline (Day 1) and up to approximately 178 weeks	Participants with worse case punctate keratopathy findings post baseline at any ocular exam by right eye, left eye and worse eye are presented as none, mild, moderate and severe. Worse eye indicates the eye with the worst visual acuity. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.
Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Baseline (Day 1) and up to approximately 178 weeks	Participants with worst-case shift from baseline in corneal examination which included: clear, pseudophakia, nuclear sclerosis, cortical cataract and posterior subcapsular cataract by right eye, left eye and worse eye are presented as yes (Y), no (N) and missing. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.
Part 2 - Percentage of Participants With Clinical Benefit Rate	Up to approximately 178 weeks	Clinical benefit rate was defined as the percentage of participants with a confirmed minimal response (MR) or better according to the IMWG Response Criteria. MR is \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%.
Part 2 - Duration of Response	Up to approximately 178 weeks	Duration of response was defined as the time from first documented evidence of PR or better, to the time when disease progression (PD) is documented per IMWG response criteria; or death due to PD occurs among participants who achieve an overall response, i.e. confirmed PR or better. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h). PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \<200 mg/24 h.
Part 2 - Time to Response	Up to approximately 178 weeks	Time to response (TTR) was defined as the time between the date of first dose and the first documented evidence of response (PR or better) among participants who achieved a confirmed response of PR or better.
Part 2 - Time to Best Response	Up to approximately 178 weeks	Time to best response was defined as the time between the date of first dose and the first best documented response (PR or better) among participants who achieved a confirmed response of PR or better.
Part 2 - Progression-free Survival	Up to approximately 178 weeks	Progression-free survival was defined as the time from first dose until the earliest date of PD per IMWG response criteria, or death due to any cause. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h).
Part 2 - Time to Disease Progression	Up to approximately 178 weeks	Time to disease progression was defined as the time from first dose until the earliest date of PD per IMWG response criteria, or death due to PD. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h).
Part 2 - Overall Survival	Up to approximately 178 weeks	Overall Survival was defined as the time from first dose until death due to any cause.
Part 1 - Maximum Concentration (Cmax) for Belantamab Mafodotin After First Dose	Pre-dose, end of infusion (EOI), 2, 4, 9, and 24 h post-SOI (start of infusion) on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for Pharmacokinetic (PK) analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 2 - Cmax for Belantamab Mafodotin After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 1 - End of Infusion Concentration (C-EOI) for Belantamab Mafodotin	EOI post belantamab mafodotin dose on Day 1 of each 21 day Cycle till Cycle 11	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 2 - C-EOI for Belantamab Mafodotin	EOI post belantamab mafodotin dose on Day 1 of each 21 day Cycle till Cycle 11	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 1 - Time of Cmax (Tmax) for Belantamab Mafodotin After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 2 - Tmax for Belantamab Mafodotin After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 1 - Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin	Pre-dose on Day 1 of each 21 day cycle from Cycle 1 until Cycle 13	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. Ctrough was calculated as the observed concentration at the end of a dosing interval, immediately before next study drug administration on Day 1 of each Cycle. PK parameter was determined using standard non-compartmental methods.
Part 2 - Ctrough for Belantamab Mafodotin	Pre-dose on Day 1 of each 21 day cycle from Cycle 1 until Cycle 13	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. Ctrough was calculated as the observed concentration at the end of a dosing interval, immediately before next study drug administration on Day 1 of each Cycle. PK parameter was determined using standard non-compartmental methods.
Part 1 - Last Time Point Where the Concentration is Above the Limit of Quantification (Tlast) for Belantamab Mafodotin After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 2 - Tlast for Belantamab Mafodotin After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 1 - Area Under Plasma Concentration-time Curve (AUC) From Time 0 to End of the Dosing Interval [AUC (0-tau)] for Belantamab Mafodotin After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 2 - AUC (0-tau) for Belantamab Mafodotin After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 1 - Cmax for Total Monoclonal Antibody (mAb) After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 2 - Cmax for Total mAb After First Dose	Pre-dose, EOI, 2, 4, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 1 - C-EOI for Total mAb	EOI post belantamab mafodotin dose on Day 1 of Cycle 1, Cycle 2, Cycle 5, Cycle 8, and Cycle 11	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 2 - C-EOI for Total mAb	EOI post belantamab mafodotin dose on Day 1 of Cycle 1, Cycle 2, and Cycle 5	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 1 - Tmax for Total mAb After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 2 - Tmax for Total mAb After First Dose	Pre-dose, EOI, 2, 4, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 1 - Ctrough for Total mAb	Cycle 1, Cycle 4, Cycle 7, Cycle 10, and Cycle 13	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. Ctrough was calculated as the observed concentration at the end of a dosing interval, immediately before next study drug administration on Day 1 of each Cycle. PK parameter was determined using standard non-compartmental methods.
Part 2 - Ctrough for Total mAb	Cycle 1 and Cycle 4	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. Ctrough was calculated as the observed concentration at the end of a dosing interval, immediately before next study drug administration on Day 1 of each Cycle. PK parameter was determined using standard non-compartmental methods.
Part 1 - Last Time Point Where the Concentration is Above the Limit of Quantification (Tlast) for Total mAb After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods. Tlast is the time of last observed quantifiable concentration of belantamab mafodotin in Cycle 1 which extended beyond protocol defined duration for some participants across treatment groups.
Part 2 - Tlast for Total mAb After First Dose	Pre-dose, EOI, 2, 4, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods. Tlast is the time of last observed quantifiable concentration of belantamab mafodotin in Cycle 1 which extended beyond protocol defined duration for some participants across treatment groups.
Part 1 - AUC (0-tau) for Total mAb After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 1 - Percentage of Participants With Overall Response Rate (ORR)	Up to approximately 178 weeks	ORR was defined as the percentage of participants with a confirmed PR or better (i.e., PR, VGPR, CR and sCR), according to the IMWG Response Criteria. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR \>= 90% reduction in serum M-component plus urine M-component \<100 mg/24 h; PR = \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 h.
Part 1 - Cmax for Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF) After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 2 - Cmax for Cys-mcMMAF After First Dose	Pre-dose, EOI, 2, 4, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 1 - C-EOI for Cys-mcMMAF After First Dose	EOI post belantamab mafodotin dose on Day 1 of Cycle 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 2 - C-EOI for Cys-mcMMAF After First Dose	EOI post belantamab mafodotin dose on Day 1 of Cycle 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 1 - Tmax for Cys-mcMMAF After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods. Tlast is the time of last observed quantifiable concentration of belantamab mafodotin in Cycle 1 which extended beyond protocol defined duration for some participants across treatment groups.
Part 2 - Tmax for Cys-mcMMAF After First Dose	Pre-dose, EOI, 2, 4, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods. Tlast is the time of last observed quantifiable concentration of belantamab mafodotin in Cycle 1 which extended beyond protocol defined duration for some participants across treatment groups.
Part 1 - Tlast for Cys-mcMMAF After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods. Tlast is the time of last observed quantifiable concentration of belantamab mafodotin in Cycle 1 which extended beyond protocol defined duration for some participants across treatment groups.
Part 2 - Tlast for Cys-mcMMAF After First Dose	Pre-dose, EOI, 2, 4, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods. Tlast is the time of last observed quantifiable concentration of belantamab mafodotin in Cycle 1 which extended beyond protocol defined duration for some participants across treatment groups.
Part 1 - AUC From Time 0 to 168 h After Dosing [AUC (0-168h)] for Cys-mcMMAF After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, and Cycle 1 Day 8	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 2 - AUC (0-168 h) for Cys-mcMMAF After First Dose	Pre-dose, EOI, 2, 4, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, and Cycle 1 Day 8	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 1 - Cmax for Pembrolizumab After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 2 - Cmax for Pembrolizumab After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 1 - Tmax for Pembrolizumab After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 2 - Tmax for Pembrolizumab After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 1 - AUC (0-tau) for Pembrolizumab After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 2 - AUC (0-tau) for Pembrolizumab After First Dose	Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 1 - Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin	Baseline (Day 1) and until end of treatment (up to 178 weeks)	Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers. At the time of primary results posting, there was no participants with positive ADA results. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.
Part 2 - Number of Participants With Post-baseline Positive ADAs Against Belantamab Mafodotin	Baseline (Day 1) and until end of treatment (up to 178 weeks)	Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers. At the time of primary results posting, there was no participants with positive ADA results. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.
Part 1 - Titers of ADAs Against Belantamab Mafodotin	Up to approximately 178 weeks	Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.
Part 2 - Titers of ADAs Against Belantamab Mafodotin	Baseline (Day 1) and up to approximately 178 weeks	Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.
Part 2 - AUC (0-tau) for Total mAb After First Dose	Pre-dose, EOI, 2, 4, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1	Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.
Part 2 - Number of Participants With AEs and SAEs	Up to approximately 178 weeks	An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function.
Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Baseline (Day 1) and up to approximately 178 weeks	Blood samples were collected for the analysis of following hematology parameters: hemoglobin, White blood cell (WBC) count, lymphocytes, neutrophils and platelet. The laboratory parameters were graded according to NCI-CTCAE version 4.03. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Any worst case post baseline increase in grade along with any increase to a maximum grade of 3 and a maximum grade of 4 are presented.
Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Baseline (Day 1) and up to approximately 178 weeks	Blood samples were collected for the analysis of following hematology parameters: basophils, eosinophils, mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), Erythrocytes, hematocrit, monocytes, neutrophils and reticulocyte. The summaries of worst-case change from baseline with respect to normal range was analyzed for only those laboratory tests that were not gradable by CTCAE version 4.03. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented.
Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Baseline (Day 1) and up to approximately 178 weeks	Blood samples were collected for the analysis of clinical chemistry parameters: glucose, alanine aminotransferase (ALT), albumin, alkaline phosphatase, aspartate aminotransferase (AST), blood bilirubin, calcium, creatine kinase (CPK), creatinine, gamma glutamyl transferase (GGT), magnesium, phosphate potassium and sodium. Laboratory parameters were graded according to NCI-CTCAE version 4.03. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Any worst case post baseline increase in grade along with any increase to a maximum grade of 3 and a maximum grade of 4 are presented.
Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Baseline (Day 1) and up to approximately 178 weeks	Blood samples were collected for the analysis of following chemistry parameters: calcium, carbon dioxide, chloride, direct bilirubin, protein, thyrotropin (TSH), thyroxine (T4) and triiodothyronine (T3). Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. The summaries of worst case change from baseline with respect to normal range was analyzed for only those laboratory tests that were not gradable by CTCAE version 4.03. The number of participants with decreases to low, changes to normal or no changes from baseline, and increases to high values have been presented.
Part 2 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Baseline (Day 1) and up to approximately 178 weeks	Urine samples were collected to assess urine glucose, protein, occult blood and ketones using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for uranalysis parameters were recorded as no change/decreased and any increase. Data for worst-case post baseline are presented.
Part 2 - Changes From Baseline in Urine Specific Gravity	Baseline (Day 1) and until end of treatment (up to 178 weeks)	Urine samples were collected from participants to assess urine specific gravity. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date
Part 2 - Changes From Baseline in Urine pH	Baseline (Day 1) and until end of treatment (up to 178 weeks)	Urine samples were collected from participants to assess urine pH levels. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.
Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: DBP and SBP	Baseline (Day 1) and up to approximately 178 weeks	DBP and SBP were measured after resting for at least 5 minutes in a supine or semi-recumbent position. They were graded according to NCI-CTCAE version 4.0. For SBP: Grade 0 (\<=120 millimeter of mercury \[mmHg\]), Grade 1 (121-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (\>=160 mmHg). For DBP: Grade 0 (\<=80 mmHg), Grade 1 (81-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (\>=100 mmHg). Higher grade indicates greater severity. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. An increase is defined as an increase in grade relative to Baseline grade. Data for worst-case post Baseline with any grade increase and a maximum post-baseline grade increase to Grade 3 from their baseline grade are presented.
Part 2 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature	Baseline (Day 1) and up to approximately 178 weeks	Vital signs (pulse rate and temperature) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. The abnormal vital sign ranges were: For pulse rate (low \<60 beats per minute \[bpm\] and high \>100 bpm); For body temperature (\<=35 degrees Celsius or \>=38 degrees Celsius). Participants were counted in the worst case category that their value changed to (low, normal or high), unless there was no change in their category. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.
Part 2 - Number of Participants With Maximum Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores	Baseline (Day 1) and up to approximately 178 weeks	BCVA score was calculated based on the Logarithm of the Minimum Angle of Resolution (logMAR score). Any maximum worst-case change from baseline categories are presented for right and left eyes. No change/improved vision is defined as a change from baseline \<0.12; a possible worsened vision is defined as a change from baseline \>=0.12 to \<0.3; a definite worsened vision is defined as a change from baseline \>=0.3 logMAR score. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.

Countries

Canada, Germany, Spain, United States

Participant flow

Recruitment details

The study consisted of two phases - Main Study Phase and Post Analysis Continued Treatment (PACT) Phase. In PACT phase those participants still benefiting from drug continued to receive study drug until discontinued or withdrawn from study.

Pre-assignment details

Total of 41 participants were enrolled in this study.

Participants by arm

Arm	Count
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation Participants were administered 2.5 mg/kg of belantamab mafodotin in combination with 200 mg of pembrolizumab via intravenous (IV) infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal , or for a maximum of 35 cycles.	6
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation Participants were administered with 3.4 mg/kg of belantamab mafodotin in combination with 200 mg of pembrolizumab via IV infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal, or for a maximum of 35 cycles.	7
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion Participants were administered belantamab mafodotin with recommended phase 2 dose (RP2D) of 2.5 mg/kg in combination with 200 mg of pembrolizumab via IV infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal, or for a maximum of 35 cycles.	28
Total	41

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003
Main Study Phase (Day 1 to Week 178)	Lost to Follow-up	0	1	0	0
Main Study Phase (Day 1 to Week 178)	Physician Decision	0	0	1	0
Main Study Phase (Day 1 to Week 178)	Withdrawal by Subject	3	2	8	0
PACT Phase (Week 178 to Week 221)	Withdrawal by Subject	0	0	0	1

Baseline characteristics

Characteristic	Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion	Total
Age, Continuous	66.8 YEARS STANDARD_DEVIATION 12.09	67.7 YEARS STANDARD_DEVIATION 9.21	61.5 YEARS STANDARD_DEVIATION 9.41	63.3 YEARS STANDARD_DEVIATION 9.92
Race/Ethnicity, Customized Asian	0 Participants	0 Participants	1 Participants	1 Participants
Race/Ethnicity, Customized Black OR African American	1 Participants	2 Participants	4 Participants	7 Participants
Race/Ethnicity, Customized White	5 Participants	5 Participants	23 Participants	33 Participants
Sex: Female, Male Female	5 Participants	4 Participants	10 Participants	19 Participants
Sex: Female, Male Male	1 Participants	3 Participants	18 Participants	22 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	2 / 6	3 / 7	7 / 28	0 / 2
other Total, other adverse events	6 / 6	6 / 7	27 / 28	0 / 2
serious Total, serious adverse events	4 / 6	5 / 7	5 / 28	0 / 2

Outcome results

Primary

Part 1 - Changes From Baseline in Urine Potential of Hydrogen (pH)

Urine samples were collected from participants to assess urine pH levels. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.

Time frame: Baseline (Day 1) and Week 46

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (MEAN)	Dispersion
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Changes From Baseline in Urine Potential of Hydrogen (pH)	1.0 Potential of Hydrogen (pH)	Standard Deviation 2.83
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Changes From Baseline in Urine Potential of Hydrogen (pH)	0.0 Potential of Hydrogen (pH)	—

Primary

Part 1 - Changes From Baseline in Urine Specific Gravity

Urine samples were collected from participants to assess urine specific gravity. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.

Time frame: Baseline (Day 1) and Week 46

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (MEAN)	Dispersion
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Changes From Baseline in Urine Specific Gravity	-0.0010 Ratio	Standard Deviation 0.00566
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Changes From Baseline in Urine Specific Gravity	0.0100 Ratio	—

Primary

Part 1 - Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function.

Time frame: Up to approximately 31 months

Population: All Treated Population included all participants who received at least one dose of study treatment.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	AEs	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	SAEs	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	AEs	7 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	SAEs	5 Participants

Primary

Part 1 - Number of Participants With Dose Limiting Toxicities (DLTs)

DLT is an AE that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 21 day DLT period and meets at least one of the DLT criteria: any Grade 4 and 3 non-hematologic toxicity, any Grade 3 or greater non-hematologic laboratory value, hematologic toxicity lasting \>=7 days, except Grade 4 thrombocytopenia of any duration or Grade 3 thrombocytopenia associated with clinically significant bleeding. Grade 3 or greater febrile neutropenia lasting \>48 hours (h) despite adequate treatment, Nephrotoxicity requiring dialysis, Liver toxicity, prolonged delay (\>14 days) in initiating Cycle 2 due to any treatment (pembrolizumab or GSK2857916) related toxicity, any treatment-related toxicity that causes discontinuation of treatment during Cycle 1, any other toxicity considered to be dose-limiting that occurs beyond 21 days and any other event which in the judgment of the investigator and GlaxoSmithKline Medical Monitor is considered to be a DLT.

Time frame: Up to 21 days

Population: All Treated Population

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Dose Limiting Toxicities (DLTs)	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Dose Limiting Toxicities (DLTs)	0 Participants

Primary

Part 1 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature

Vital signs (pulse rate and temperature) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. The abnormal vital sign ranges were: For pulse rate (low \<60 beats per minute \[bpm\] and high \>100 bpm); For body temperature (\<=35 degrees Celsius or \>=38 degrees Celsius). Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case change from baseline was presented as Baseline to low, Baseline to Normal or No change and Baseline to High.

Time frame: Baseline (Day 1) and up to approximately 31 months

Population: All Treated Population

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature	Pulse Rate	Baseline To Low	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature	Pulse Rate	Baseline To Normal or No Change	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature	Pulse Rate	Baseline To High	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature	Temperature	Baseline To Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature	Temperature	Baseline To Normal or No Change	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature	Temperature	Baseline To High	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature	Temperature	Baseline To Normal or No Change	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature	Pulse Rate	Baseline To Low	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature	Temperature	Baseline To Low	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature	Pulse Rate	Baseline To Normal or No Change	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature	Temperature	Baseline To High	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature	Pulse Rate	Baseline To High	2 Participants

Primary

Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters

Blood samples were collected for the analysis of following hematology parameters: basophils, eosinophils, mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), erythrocytes, hematocrit, monocytes, neutrophils and reticulocyte. The summaries of worst-case change from baseline with respect to normal range was analyzed for only those laboratory tests that were not gradable by CTCAE version 4.03. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented.

Time frame: Baseline (Day 1) and up to approximately 31 months

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Basophils, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCH, Increase to High	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCV, Decrease to Low	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Eosinophils, Change to Normal or No Change	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCV, Change to Normal or No Change	5 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCV, Increase to High	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Eosinophils, Increase to High	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Erythrocytes, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Basophils, Change to Normal or No Change	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Erythrocytes, Change to Normal or No Change	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCHC, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Erythrocytes, Increase to High	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Reticulocyte, Increase to High	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Hematocrit, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCHC, Change to Normal or No Change	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Hematocrit, Change to Normal or No Change	5 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Basophils, Increase to High	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Hematocrit, Increase to High	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCHC, Increase to High	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Monocytes, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Reticulocyte, Change to Normal or No Change	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Monocytes, Change to Normal or No Change	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCH, Decrease to Low	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Monocytes, Increase to High	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Eosinophils, Decrease to Low	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Reticulocyte, Decrease to Low	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCH, Change to Normal or No Change	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Reticulocyte, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Reticulocyte, Change to Normal or No Change	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Reticulocyte, Increase to High	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Basophils, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Basophils, Change to Normal or No Change	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Basophils, Increase to High	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Eosinophils, Decrease to Low	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Eosinophils, Change to Normal or No Change	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Eosinophils, Increase to High	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCHC, Decrease to Low	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCHC, Change to Normal or No Change	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCHC, Increase to High	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCH, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCH, Change to Normal or No Change	5 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCV, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCV, Change to Normal or No Change	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCV, Increase to High	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Erythrocytes, Decrease to Low	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Erythrocytes, Change to Normal or No Change	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Erythrocytes, Increase to High	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Hematocrit, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Hematocrit, Change to Normal or No Change	7 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Hematocrit, Increase to High	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Monocytes, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Monocytes, Change to Normal or No Change	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Monocytes, Increase to High	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCH, Increase to High	1 Participants

Primary

Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters

Blood samples were collected for the analysis of following chemistry parameters: calcium, carbon dioxide, chloride, direct bilirubin, protein, thyrotropin (TSH), thyroxine (T4) and triiodothyronine (T3). The summaries of worst case change from baseline with respect to normal range was analyzed for only those laboratory tests that were not gradable by CTCAE version 4.03. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented.

Time frame: Baseline (Day 1) and up to 31 months

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Calcium, Change to Normal or No Change	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Carbon dioxide, Decrease to Low	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Direct bilirubin, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Direct bilirubin, Increase to High	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	T4, Decrease to Low	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	T3, Increase to High	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Calcium, Decrease to Low	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Calcium, Increase to High	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Carbon dioxide, Change to Normal or No Change	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Carbon dioxide, Increase to High	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Chloride, Decrease to Low	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Chloride, Change to Normal or No Change	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Chloride, Increase to High	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Direct bilirubin, Change to Normal or No Change	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Protein, Decrease to Low	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Protein, Change to Normal or No Change	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Protein, Increase to High	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	TSH, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	TSH, Change to Normal or No Change	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	TSH, Increase to High	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	T4, Change to Normal or No Change	5 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	T4, Increase to High	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	T3, Decrease to Low	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	T3, Change to Normal or No Change	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	TSH, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Chloride, Increase to High	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Carbon dioxide, Increase to High	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Direct bilirubin, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	T3, Decrease to Low	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Direct bilirubin, Increase to High	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Direct bilirubin, Change to Normal or No Change	5 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	T4, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	T4, Change to Normal or No Change	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	T3, Change to Normal or No Change	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	TSH, Change to Normal or No Change	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Protein, Decrease to Low	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Calcium, Decrease to Low	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Calcium, Change to Normal or No Change	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	T4, Increase to High	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Calcium, Increase to High	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Carbon dioxide, Decrease to Low	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Protein, Change to Normal or No Change	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Carbon dioxide, Change to Normal or No Change	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	TSH, Increase to High	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Protein, Increase to High	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Chloride, Decrease to Low	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	T3, Increase to High	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Chloride, Change to Normal or No Change	4 Participants

Primary

Part 1 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results

Urine samples were collected to assess urine glucose, protein, occult blood and ketones using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase. Data for worst-case post baseline urinalysis results is presented.

Time frame: Baseline (Day 1) and up to approximately 31 months

Population: All Treated Population. Only those participants with data available for worst-case post baseline have been presented.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Glucose, Any Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Occult Blood, No Change/Decreased	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Glucose, No Change/Decreased	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Ketones, No Change/Decreased	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Ketones, Any Increase	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Occult Blood, Any Increase	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Protein, No Change/Decreased	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Protein, Any Increase	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Protein, Any Increase	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Ketones, Any Increase	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Occult Blood, No Change/Decreased	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Protein, No Change/Decreased	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Glucose, No Change/Decreased	5 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Glucose, Any Increase	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Occult Blood, Any Increase	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Ketones, No Change/Decreased	5 Participants

Primary

Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters

Blood samples were collected for the analysis of following hematology parameters: hemoglobin, White blood cells (WBC) count, lymphocytes, neutrophils and platelet count. The laboratory parameters were graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Any worst-case post baseline increase in grade along with any increase to a maximum grade of 3 and a maximum grade of 4 are presented.

Time frame: Baseline (Day 1) and up to approximately 31 months

Population: All Treated Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Hemoglobin Increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	WBC Decreased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Hemoglobin Decreased (Anemia), Increase to Grade 3	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Lymphocyte Decreased, Any Grade Increase	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	WBC Increased (Leukocytosis), Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Lymphocyte Decreased, Increase to Grade 3	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Hemoglobin Increased, Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Lymphocyte Decreased, Increase to Grade 4	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	WBC Increased (Leukocytosis), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Lymphocyte Increased, Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Hemoglobin Decreased (Anemia), Any Grade Increase	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Lymphocyte Increased, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Lymphocyte Increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Neutrophil Decreased, Any Grade Increase	5 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	WBC Increased (Leukocytosis), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Neutrophil Decreased, Increase to Grade 3	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Neutrophil Decreased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Hemoglobin Increased, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Platelet Decreased, Any Grade Increase	5 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	WBC Decreased, Any Grade Increase	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Platelet Decreased, Increase to Grade 3	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Hemoglobin Decreased (Anemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Platelet Decreased, Increase to Grade 4	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	WBC Decreased, Increase to Grade 3	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Platelet Decreased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Lymphocyte Increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Neutrophil Decreased, Increase to Grade 3	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Hemoglobin Decreased (Anemia), Any Grade Increase	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Hemoglobin Decreased (Anemia), Increase to Grade 3	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Hemoglobin Decreased (Anemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Hemoglobin Increased, Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Hemoglobin Increased, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Hemoglobin Increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	WBC Increased (Leukocytosis), Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	WBC Increased (Leukocytosis), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	WBC Increased (Leukocytosis), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	WBC Decreased, Any Grade Increase	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	WBC Decreased, Increase to Grade 3	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	WBC Decreased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Lymphocyte Decreased, Any Grade Increase	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Lymphocyte Decreased, Increase to Grade 3	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Lymphocyte Decreased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Lymphocyte Increased, Any Grade Increase	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Neutrophil Decreased, Any Grade Increase	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Neutrophil Decreased, Increase to Grade 4	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Platelet Decreased, Any Grade Increase	5 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Platelet Decreased, Increase to Grade 3	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Lymphocyte Increased, Increase to Grade 3	0 Participants

Primary

Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters

Blood samples were collected for the analysis of clinical chemistry parameters: glucose, alanine aminotransferase (ALT), albumin, alkaline phosphatase, aspartate aminotransferase (AST), blood bilirubin, calcium, creatine kinase (CPK), creatinine, gamma glutamyl transferase (GGT), magnesium, phosphate, potassium and sodium. Laboratory parameters were graded according to NCI-CTCAE version 4.03. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Any worst case post baseline increase in grade along with any increase to a maximum grade of 3 and a maximum grade of 4 are presented.

Time frame: Baseline (Day 1) and up to approximately 31 months

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Blood bilirubin Increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Glucose Decreased (Hypoglycemia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Calcium Increased (Hypercalcemia), Any Grade Increase	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Calcium Increased (Hypercalcemia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Glucose Decreased (Hypoglycemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Calcium Increased (Hypercalcemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Magnesium Decreased (Hypomagnesemia), Any Grade Increase	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Calcium Decreased (Hypocalcemia), Any Grade Increase	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Calcium Decreased (Hypocalcemia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	ALT Increased, Any Grade Increase	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	CPK Increased, Any Grade Increase	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Calcium Decreased (Hypocalcemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	ALT Increased, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	CPK Increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Potassium Increased (Hyperkalemia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Creatinine Increased, Any Grade Increase	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	ALT Increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Creatinine Increased, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	CPK Increased, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Creatinine Increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Albumin Decreased (Hypoalbuminemia), Any Grade Increase	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	GGT Increased, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Albumin Decreased (Hypoalbuminemia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	GGT Increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Albumin Decreased (Hypoalbuminemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Sodium Increased (Hypernatremia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Alkaline phosphatase Increased, Any Grade Increase	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Magnesium Increased (Hypermagnesemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Sodium Decreased (Hyponatremia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Magnesium Decreased (Hypomagnesemia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Magnesium Decreased (Hypomagnesemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Alkaline phosphatase Increased, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Phosphate Decreased (Hypophosphatemia), Any Grade Increase	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Glucose Increased (Hyperglycemia), Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Phosphate Decreased (Hypophosphatemia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Alkaline phosphatase Increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Phosphate Decreased (Hypophosphatemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	GGT Increased, Any Grade Increase	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Potassium Increased (Hyperkalemia), Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	AST Increased, Any Grade Increase	5 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Potassium Increased (Hyperkalemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Glucose Increased (Hyperglycemia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Potassium Decreased (Hypokalemia), Any Grade Increase	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	AST Increased, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Potassium Decreased (Hypokalemia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Magnesium Increased (Hypermagnesemia), Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Potassium Decreased (Hypokalemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Sodium Increased (Hypernatremia), Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	AST Increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Blood bilirubin Increased, Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Sodium Increased (Hypernatremia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Glucose Decreased (Hypoglycemia), Any Grade Increase	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Sodium Decreased (Hyponatremia), Any Grade Increase	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Blood bilirubin Increased, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Magnesium Increased (Hypermagnesemia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Sodium Decreased (Hyponatremia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Glucose Increased (Hyperglycemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Sodium Decreased (Hyponatremia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Glucose Increased (Hyperglycemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Albumin Decreased (Hypoalbuminemia), Any Grade Increase	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	AST Increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Calcium Decreased (Hypocalcemia), Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Calcium Decreased (Hypocalcemia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Creatinine Increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Magnesium Increased (Hypermagnesemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Magnesium Decreased (Hypomagnesemia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Potassium Increased (Hyperkalemia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Potassium Decreased (Hypokalemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Glucose Increased (Hyperglycemia), Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Glucose Increased (Hyperglycemia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Glucose Decreased (Hypoglycemia), Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Glucose Decreased (Hypoglycemia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Glucose Decreased (Hypoglycemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	ALT Increased, Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	ALT Increased, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	ALT Increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Albumin Decreased (Hypoalbuminemia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Albumin Decreased (Hypoalbuminemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Alkaline phosphatase Increased, Any Grade Increase	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Alkaline phosphatase Increased, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Alkaline phosphatase Increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	AST Increased, Any Grade Increase	5 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	AST Increased, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Blood bilirubin Increased, Any Grade Increase	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Blood bilirubin Increased, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Blood bilirubin Increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Calcium Increased (Hypercalcemia), Any Grade Increase	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Calcium Increased (Hypercalcemia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Calcium Increased (Hypercalcemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Calcium Decreased (Hypocalcemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	CPK Increased, Any Grade Increase	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	CPK Increased, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	CPK Increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Creatinine Increased, Any Grade Increase	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Creatinine Increased, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	GGT Increased, Any Grade Increase	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	GGT Increased, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	GGT Increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Magnesium Increased (Hypermagnesemia), Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Magnesium Increased (Hypermagnesemia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Magnesium Decreased (Hypomagnesemia), Any Grade Increase	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Magnesium Decreased (Hypomagnesemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Phosphate Decreased (Hypophosphatemia), Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Phosphate Decreased (Hypophosphatemia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Phosphate Decreased (Hypophosphatemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Potassium Increased (Hyperkalemia), Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Potassium Increased (Hyperkalemia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Potassium Decreased (Hypokalemia), Any Grade Increase	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Potassium Decreased (Hypokalemia), Increase to Grade 3	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Sodium Increased (Hypernatremia), Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Sodium Increased (Hypernatremia), Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Sodium Increased (Hypernatremia), Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Sodium Decreased (Hyponatremia), Any Grade Increase	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Sodium Decreased (Hyponatremia), Increase to Grade 3	2 Participants

Primary

Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)

DBP and SBP were measured after resting for at least 5 minutes in a supine or semi-recumbent position. They were graded according to NCI-CTCAE version 4.03. For SBP: Grade 0 (\<=120 millimeter of mercury \[mmHg\]), Grade 1 (121-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (\>=160 mmHg). For DBP: Grade 0 (\<=80 mmHg), Grade 1 (81-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (\>=100 mmHg). Higher grade indicates greater severity. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post baseline with any grade increase and a maximum post-baseline grade increase to Grade 3 from their baseline grade are presented.

Time frame: Baseline (Day 1) and up to approximately 31 months

Population: All Treated Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)	DBP, Any Grade Increase	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)	DBP, Increase to Grade 2	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)	DBP, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)	SBP, Any Grade Increase	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)	SBP, Increase to Grade 2	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)	SBP, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)	SBP, Increase to Grade 2	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)	DBP, Any Grade Increase	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)	SBP, Any Grade Increase	5 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)	DBP, Increase to Grade 2	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)	SBP, Increase to Grade 3	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)	DBP, Increase to Grade 3	0 Participants

Primary

Part 2 - Percentage of Participants With Overall Response Rate (ORR)

ORR was defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response \[VGPR\], complete response \[CR\] and stringent complete response \[sCR\]), according to the International Myeloma Working Group (IMWG) Response Criteria. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h; PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h.

Time frame: Up to approximately 31 months

Population: All Treated Population

Arm	Measure	Value (NUMBER)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Percentage of Participants With Overall Response Rate (ORR)	43 Percentage of Participants

Secondary

Part 1 - Area Under Plasma Concentration-time Curve (AUC) From Time 0 to End of the Dosing Interval [AUC (0-tau)] for Belantamab Mafodotin After First Dose

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Due to bioanalytical issues, PK data were not collected and analyzed for belantamab mafodotin. Therefore, this PK parameter was not reported in this study

Secondary

Part 1 - AUC (0-tau) for Pembrolizumab After First Dose

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Pembrolizumab data were not collected and analyzed. Therefore, this PK parameter was not reported in this study.

Secondary

Part 1 - AUC (0-tau) for Total mAb After First Dose

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - AUC (0-tau) for Total mAb After First Dose	6237.2 h*ug/mL	Geometric Coefficient of Variation 17.9
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - AUC (0-tau) for Total mAb After First Dose	10817.8 h*ug/mL	Geometric Coefficient of Variation 48.5

Secondary

Part 1 - AUC From Time 0 to 168 h After Dosing [AUC (0-168h)] for Cys-mcMMAF After First Dose

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, and Cycle 1 Day 8

Population: Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - AUC From Time 0 to 168 h After Dosing [AUC (0-168h)] for Cys-mcMMAF After First Dose	155.27 h*ug/mL	—
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - AUC From Time 0 to 168 h After Dosing [AUC (0-168h)] for Cys-mcMMAF After First Dose	90.61 h*ug/mL	Geometric Coefficient of Variation 34.5

Secondary

Part 1 - C-EOI for Cys-mcMMAF After First Dose

Time frame: EOI post belantamab mafodotin dose on Day 1 of Cycle 1

Population: Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - C-EOI for Cys-mcMMAF After First Dose	0.7110 ng/mL
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - C-EOI for Cys-mcMMAF After First Dose	0.7630 ng/mL

Secondary

Part 1 - C-EOI for Total mAb

Time frame: EOI post belantamab mafodotin dose on Day 1 of Cycle 1, Cycle 2, Cycle 5, Cycle 8, and Cycle 11

Population: Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Group	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - C-EOI for Total mAb	Cycle 8	63.70 ug/mL
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - C-EOI for Total mAb	Cycle 1	40.15 ug/mL
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - C-EOI for Total mAb	Cycle 2	53.90 ug/mL
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - C-EOI for Total mAb	Cycle 5	54.65 ug/mL
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - C-EOI for Total mAb	Cycle 11	65.40 ug/mL
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - C-EOI for Total mAb	Cycle 11	54.80 ug/mL
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - C-EOI for Total mAb	Cycle 8	39.75 ug/mL
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - C-EOI for Total mAb	Cycle 5	73.90 ug/mL
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - C-EOI for Total mAb	Cycle 2	64.65 ug/mL
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - C-EOI for Total mAb	Cycle 1	65.30 ug/mL

Secondary

Part 1 - Cmax for Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF) After First Dose

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Cmax for Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF) After First Dose	1.5799 ng/mL	Geometric Coefficient of Variation 30.4
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Cmax for Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF) After First Dose	1.0966 ng/mL	Geometric Coefficient of Variation 40.9

Secondary

Part 1 - Cmax for Pembrolizumab After First Dose

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Pembrolizumab data were not collected and analyzed. Therefore, this PK parameter was not reported in this study.

Secondary

Part 1 - Cmax for Total Monoclonal Antibody (mAb) After First Dose

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Cmax for Total Monoclonal Antibody (mAb) After First Dose	43.57 ug/mL	Geometric Coefficient of Variation 7.1
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Cmax for Total Monoclonal Antibody (mAb) After First Dose	64.45 ug/mL	Geometric Coefficient of Variation 21.5

Secondary

Part 1 - Ctrough for Total mAb

Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. Ctrough was calculated as the observed concentration at the end of a dosing interval, immediately before next study drug administration on Day 1 of each Cycle. PK parameter was determined using standard non-compartmental methods.

Time frame: Cycle 1, Cycle 4, Cycle 7, Cycle 10, and Cycle 13

Population: Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Group	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Ctrough for Total mAb	Cycle 4	8.91 ug/mL
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Ctrough for Total mAb	Cycle 10	18.40 ug/mL
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Ctrough for Total mAb	Cycle 1	5.420 ug/mL
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Ctrough for Total mAb	Cycle 13	18.05 ug/mL
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Ctrough for Total mAb	Cycle 7	26.90 ug/mL
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Ctrough for Total mAb	Cycle 1	13.350 ug/mL
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Ctrough for Total mAb	Cycle 7	45.05 ug/mL
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Ctrough for Total mAb	Cycle 4	18.80 ug/mL
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Ctrough for Total mAb	Cycle 10	21.70 ug/mL

Secondary

Part 1 - End of Infusion Concentration (C-EOI) for Belantamab Mafodotin

Time frame: EOI post belantamab mafodotin dose on Day 1 of each 21 day Cycle till Cycle 11

Population: Pharmacokinetic Population. Due to bioanalytical issues, PK data were not collected and analyzed for belantamab mafodotin. Therefore, this PK parameter was not reported in this study

Secondary

Part 1 - Last Time Point Where the Concentration is Above the Limit of Quantification (Tlast) for Belantamab Mafodotin After First Dose

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Due to bioanalytical issues, PK data were not collected and analyzed for belantamab mafodotin. Therefore, this PK parameter was not reported in this study

Secondary

Part 1 - Last Time Point Where the Concentration is Above the Limit of Quantification (Tlast) for Total mAb After First Dose

Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods. Tlast is the time of last observed quantifiable concentration of belantamab mafodotin in Cycle 1 which extended beyond protocol defined duration for some participants across treatment groups.

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Last Time Point Where the Concentration is Above the Limit of Quantification (Tlast) for Total mAb After First Dose	501.800 Hour
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Last Time Point Where the Concentration is Above the Limit of Quantification (Tlast) for Total mAb After First Dose	481.580 Hour

Secondary

Part 1 - Maximum Concentration (Cmax) for Belantamab Mafodotin After First Dose

Blood samples were collected for Pharmacokinetic (PK) analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.

Time frame: Pre-dose, end of infusion (EOI), 2, 4, 9, and 24 h post-SOI (start of infusion) on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic (PK) Population included participants in the all treated population from whom at least one PK sample was obtained and analyzed for belantamab mafodotin. Due to bioanalytical issues, PK data were not collected and analyzed for belantamab mafodotin. Therefore, this PK parameter was not reported in this study.

Secondary

Part 1 - Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers. At the time of primary results posting, there was no participants with positive ADA results. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.

Time frame: Baseline (Day 1) and until end of treatment (up to 178 weeks)

Population: All Treated Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin	Baseline	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin	End of Treatment	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin	Baseline	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin	End of Treatment	0 Participants

Secondary

Part 1 - Percentage of Participants With Overall Response Rate (ORR)

ORR was defined as the percentage of participants with a confirmed PR or better (i.e., PR, VGPR, CR and sCR), according to the IMWG Response Criteria. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR \>= 90% reduction in serum M-component plus urine M-component \<100 mg/24 h; PR = \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 h.

Time frame: Up to approximately 178 weeks

Population: All Treated Population

Arm	Measure	Value (NUMBER)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Percentage of Participants With Overall Response Rate (ORR)	67 Percentage of Participants
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Percentage of Participants With Overall Response Rate (ORR)	43 Percentage of Participants

Secondary

Part 1 - Time of Cmax (Tmax) for Belantamab Mafodotin After First Dose

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Due to bioanalytical issues, PK data were not collected and analyzed for belantamab mafodotin. Therefore, this PK parameter was not reported in this study

Secondary

Part 1 - Titers of ADAs Against Belantamab Mafodotin

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.

Time frame: Up to approximately 178 weeks

Population: All Treated Population. There were no participants with positive ADA results. Hence the titer (concentration) of ADA was not collected.

Secondary

Part 1 - Tlast for Cys-mcMMAF After First Dose

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Tlast for Cys-mcMMAF After First Dose	161.380 Hour
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Tlast for Cys-mcMMAF After First Dose	171.250 Hour

Secondary

Part 1 - Tmax for Cys-mcMMAF After First Dose

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Tmax for Cys-mcMMAF After First Dose	13.510 Hour
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Tmax for Cys-mcMMAF After First Dose	4.120 Hour

Secondary

Part 1 - Tmax for Pembrolizumab After First Dose

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Pembrolizumab data were not collected and analyzed. Therefore, this PK parameter was not reported in this study.

Secondary

Part 1 - Tmax for Total mAb After First Dose

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Tmax for Total mAb After First Dose	1.100 Hour
Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation	Part 1 - Tmax for Total mAb After First Dose	1.520 Hour

Secondary

Part 1 - Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin

Time frame: Pre-dose on Day 1 of each 21 day cycle from Cycle 1 until Cycle 13

Population: Pharmacokinetic Population. Due to bioanalytical issues, PK data were not collected and analyzed for belantamab mafodotin. Therefore, this PK parameter was not reported in this study

Secondary

Part 2 - AUC (0-168 h) for Cys-mcMMAF After First Dose

Time frame: Pre-dose, EOI, 2, 4, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, and Cycle 1 Day 8

Population: Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - AUC (0-168 h) for Cys-mcMMAF After First Dose	128.38 h*ug/mL	Geometric Coefficient of Variation 70.9

Secondary

Part 2 - AUC (0-tau) for Belantamab Mafodotin After First Dose

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Due to bioanalytical issues, PK data were not collected and analyzed for belantamab mafodotin. Therefore, this PK parameter was not reported in this study

Secondary

Part 2 - AUC (0-tau) for Pembrolizumab After First Dose

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Pembrolizumab data were not collected and analyzed. Therefore, this PK parameter was not reported in this study.

Secondary

Part 2 - AUC (0-tau) for Total mAb After First Dose

Time frame: Pre-dose, EOI, 2, 4, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - AUC (0-tau) for Total mAb After First Dose	7949.0 h*ug/mL	Geometric Coefficient of Variation 27.2

Secondary

Part 2 - C-EOI for Belantamab Mafodotin

Time frame: EOI post belantamab mafodotin dose on Day 1 of each 21 day Cycle till Cycle 11

Population: Pharmacokinetic Population. Due to bioanalytical issues, PK data were not collected and analyzed for belantamab mafodotin. Therefore, this PK parameter was not reported in this study

Secondary

Part 2 - C-EOI for Cys-mcMMAF After First Dose

Time frame: EOI post belantamab mafodotin dose on Day 1 of Cycle 1

Population: Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - C-EOI for Cys-mcMMAF After First Dose	0.3150 ng/mL

Secondary

Part 2 - C-EOI for Total mAb

Time frame: EOI post belantamab mafodotin dose on Day 1 of Cycle 1, Cycle 2, and Cycle 5

Population: Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Group	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - C-EOI for Total mAb	Cycle 1	48.60 ug/mL
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - C-EOI for Total mAb	Cycle 2	53.00 ug/mL
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - C-EOI for Total mAb	Cycle 5	52.35 ug/mL

Secondary

Part 2 - Changes From Baseline in Urine pH

Urine samples were collected from participants to assess urine pH levels. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.

Time frame: Baseline (Day 1) and until end of treatment (up to 178 weeks)

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Changes From Baseline in Urine pH	Baseline	5.71 Potential of Hydrogen (pH)	Standard Deviation 0.844
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Changes From Baseline in Urine pH	End of Treatment	0.10 Potential of Hydrogen (pH)	Standard Deviation 0.687

Secondary

Part 2 - Changes From Baseline in Urine Specific Gravity

Urine samples were collected from participants to assess urine specific gravity. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date

Time frame: Baseline (Day 1) and until end of treatment (up to 178 weeks)

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Changes From Baseline in Urine Specific Gravity	End of Treatment	-0.0001 Ratio	Standard Deviation 0.00813
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Changes From Baseline in Urine Specific Gravity	Baseline	1.0171 Ratio	Standard Deviation 0.00965

Secondary

Part 2 - Cmax for Belantamab Mafodotin After First Dose

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Due to bioanalytical issues, PK data were not collected and analyzed for belantamab mafodotin. Therefore, this PK parameter was not reported in this study

Secondary

Part 2 - Cmax for Cys-mcMMAF After First Dose

Time frame: Pre-dose, EOI, 2, 4, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Cmax for Cys-mcMMAF After First Dose	1.2481 ng/mL	Geometric Coefficient of Variation 111.5

Secondary

Part 2 - Cmax for Pembrolizumab After First Dose

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Pembrolizumab data were not collected and analyzed. Therefore, this PK parameter was not reported in this study.

Secondary

Part 2 - Cmax for Total mAb After First Dose

Time frame: Pre-dose, EOI, 2, 4, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Cmax for Total mAb After First Dose	46.70 ug/mL	Geometric Coefficient of Variation 23.3

Secondary

Part 2 - Ctrough for Belantamab Mafodotin

Time frame: Pre-dose on Day 1 of each 21 day cycle from Cycle 1 until Cycle 13

Population: Pharmacokinetic Population. Due to bioanalytical issues, PK data were not collected and analyzed for belantamab mafodotin. Therefore, this PK parameter was not reported in this study

Secondary

Part 2 - Ctrough for Total mAb

Time frame: Cycle 1 and Cycle 4

Population: Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Group	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Ctrough for Total mAb	Cycle 1	7.735 ug/mL
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Ctrough for Total mAb	Cycle 4	11.60 ug/mL

Secondary

Part 2 - Duration of First Occurrence of Worsening in BCVA Score

The time from onset of any visual acuity event (change from baseline logMAR score \>= 0.3 in either eye) until the event is resolved (change from baseline logMAR score \< 0.3 in both eyes) was used to calculate the duration of first occurrence.

Time frame: Up to approximately 178 weeks

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Duration of First Occurrence of Worsening in BCVA Score	47.0 Days

Secondary

Part 2 - Duration of Resolution Post-treatment Exposure of Worsening in BCVA Score

The time taken for the resolution of worsening eye post treatment exposure. Duration was defined as the time from onset of any visual acuity event (change from baseline logMAR score \>= 0.3 in either eye) until the event was considered resolved (change from baseline logMAR score \< 0.3 in both eyes). It required at least a one day gap between the resolution of all events from first occurrence to the onset of second occurrence. The end of treatment exposure was defined as 20 days from last infusion date.

Time frame: Up to approximately 178 weeks

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Duration of Resolution Post-treatment Exposure of Worsening in BCVA Score	34.5 Days

Secondary

Part 2 - Duration of Response

Duration of response was defined as the time from first documented evidence of PR or better, to the time when disease progression (PD) is documented per IMWG response criteria; or death due to PD occurs among participants who achieve an overall response, i.e. confirmed PR or better. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h). PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \<200 mg/24 h.

Time frame: Up to approximately 178 weeks

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Duration of Response	7.6 Months

Secondary

Part 2 - Number of Participants According to the Number of Definite Events of Worsening of Vision

A definite worsened vision was defined as a change from baseline \>=0.3 logMAR score.

Time frame: Up to approximately 178 weeks

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants According to the Number of Definite Events of Worsening of Vision	One	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants According to the Number of Definite Events of Worsening of Vision	Two	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants According to the Number of Definite Events of Worsening of Vision	Three or more	3 Participants

Secondary

Part 2 - Number of Participants With AEs and SAEs

Time frame: Up to approximately 178 weeks

Population: All Treated Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With AEs and SAEs	AEs	27 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With AEs and SAEs	SAEs	5 Participants

Secondary

Part 2 - Number of Participants With Maximum Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores

BCVA score was calculated based on the Logarithm of the Minimum Angle of Resolution (logMAR score). Any maximum worst-case change from baseline categories are presented for right and left eyes. No change/improved vision is defined as a change from baseline \<0.12; a possible worsened vision is defined as a change from baseline \>=0.12 to \<0.3; a definite worsened vision is defined as a change from baseline \>=0.3 logMAR score. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.

Time frame: Baseline (Day 1) and up to approximately 178 weeks

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Maximum Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores	Left Eye, No change/improved vision	14 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Maximum Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores	Left Eye, Definite worsened vision	8 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Maximum Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores	Left Eye, Possible worsened vision	5 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Maximum Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores	Right Eye, No change/improved vision	16 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Maximum Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores	Right Eye, Possible worsened vision	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Maximum Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores	Right Eye, Definite worsened vision	7 Participants

Secondary

Part 2 - Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception

Time frame: Baseline (Day 1) and up to approximately 178 weeks

Population: All Treated Population. Data was not collected

Secondary

Part 2 - Number of Participants With Post-baseline Positive ADAs Against Belantamab Mafodotin

Time frame: Baseline (Day 1) and until end of treatment (up to 178 weeks)

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Post-baseline Positive ADAs Against Belantamab Mafodotin	Baseline	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Post-baseline Positive ADAs Against Belantamab Mafodotin	End of Treatment	0 Participants

Secondary

Part 2 - Number of Participants With Resolution of Post Treatment Exposure Worsening in BCVA Score

The event was considered resolved if the change from baseline in logMAR score \< 0.3 in both eyes.

Time frame: Up to approximately 178 weeks

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Resolution of Post Treatment Exposure Worsening in BCVA Score	Resolved	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Resolution of Post Treatment Exposure Worsening in BCVA Score	Not resolved, follow-up ongoing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Resolution of Post Treatment Exposure Worsening in BCVA Score	Not resolved, follow-up ended	2 Participants

Secondary

Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings

Participants with worse case punctate keratopathy findings post baseline at any ocular exam by right eye, left eye and worse eye are presented as none, mild, moderate and severe. Worse eye indicates the eye with the worst visual acuity. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.

Time frame: Baseline (Day 1) and up to approximately 178 weeks

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Right eye, Worst findings	Mild	11 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Right eye, Worst findings	Moderate	7 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Left eye, Worst findings	Mild	9 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Left eye, Worst findings	Moderate	9 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Right eye, Most frequent findings	Mild	14 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Right eye, Most frequent findings	Moderate	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Left eye, Most frequent findings	Mild	13 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Left eye, Most frequent findings	Moderate	5 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Left eye, Most frequent findings	Severe	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Worst eye, Most frequent findings	None	7 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Worst eye, Most frequent findings	Mild	14 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Right eye, Worst findings	None	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Right eye, Worst findings	Severe	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Left eye, Worst findings	None	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Left eye, Worst findings	Severe	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Worst eye, Worst findings	None	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Worst eye, Worst findings	Mild	8 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Worst eye, Worst findings	Moderate	10 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Worst eye, Worst findings	Severe	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Right eye, Most frequent findings	None	10 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Right eye, Most frequent findings	Severe	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Left eye, Most frequent findings	None	8 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Worst eye, Most frequent findings	Moderate	5 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings	Worst eye, Most frequent findings	Severe	0 Participants

Secondary

Part 2 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature

Vital signs (pulse rate and temperature) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. The abnormal vital sign ranges were: For pulse rate (low \<60 beats per minute \[bpm\] and high \>100 bpm); For body temperature (\<=35 degrees Celsius or \>=38 degrees Celsius). Participants were counted in the worst case category that their value changed to (low, normal or high), unless there was no change in their category. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.

Time frame: Baseline (Day 1) and up to approximately 178 weeks

Population: All Treated Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature	Pulse Rate, To High	7 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature	Temperature, To Low	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature	Temperature, To Normal or No Change	23 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature	Temperature, To High	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature	Pulse Rate, To Low	10 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature	Pulse Rate, To Normal or No Change	11 Participants

Secondary

Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters

Blood samples were collected for the analysis of following hematology parameters: basophils, eosinophils, mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), Erythrocytes, hematocrit, monocytes, neutrophils and reticulocyte. The summaries of worst-case change from baseline with respect to normal range was analyzed for only those laboratory tests that were not gradable by CTCAE version 4.03. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented.

Time frame: Baseline (Day 1) and up to approximately 178 weeks

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Basophils, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Eosinophils, Increase to High	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Erythrocytes, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Erythrocytes, Change to Normal or No Change	26 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Hematocrit, Change to Normal or No Change	23 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Basophils, Change to Normal or No Change	22 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Basophils, Increase to High	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Eosinophils, Decrease to Low	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Eosinophils, Change to Normal or No Change	22 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCHC, Decrease to Low	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCHC, Change to Normal or No Change	24 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCHC, Increase to High	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCH, Decrease to Low	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCH, Change to Normal or No Change	16 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCH, Increase to High	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCV, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCV, Change to Normal or No Change	25 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	MCV, Increase to High	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Erythrocytes, Increase to High	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Hematocrit, Decrease to Low	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Hematocrit, Increase to High	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Monocytes, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Monocytes, Change to Normal or No Change	20 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Monocytes, Increase to High	7 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Neutrophils, Segmented, Decrease to Low	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Neutrophils, Segmented, Change to Normal or No Change	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Neutrophils, Segmented, Increase to High	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Reticulocytes, Decrease to Low	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Reticulocytes, Change to Normal or No Change	14 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters	Reticulocytes, Increase to High	5 Participants

Secondary

Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters

Blood samples were collected for the analysis of following chemistry parameters: calcium, carbon dioxide, chloride, direct bilirubin, protein, thyrotropin (TSH), thyroxine (T4) and triiodothyronine (T3). Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. The summaries of worst case change from baseline with respect to normal range was analyzed for only those laboratory tests that were not gradable by CTCAE version 4.03. The number of participants with decreases to low, changes to normal or no changes from baseline, and increases to high values have been presented.

Time frame: Baseline (Day 1) and up to approximately 178 weeks

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed. Participants are counted twice if the participant has values that changed Decreased to Low and Increased to High, so the sum of the percentages may not add to 100% for each row

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Carbon Dioxide, Change to Normal or No Change	14 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Carbon Dioxide, Increase to High	9 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Direct Bilirubin, Increase to High	7 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Calcium, Decrease to Low	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Calcium, Change to Normal or No Change	18 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Calcium, Increase to High	5 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Carbon Dioxide, Decrease to Low	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Chloride, Decrease to Low	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Chloride, Change to Normal or No Change	20 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Chloride, Increase to High	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Direct Bilirubin, Decrease to Low	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Direct Bilirubin, Change to Normal or No Change	15 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Protein, Decrease to Low	8 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Protein, Change to Normal or No Change	18 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	Protein, Increase to High	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	TSH, Decrease to Low	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	TSH, Change to Normal or No Change	17 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	TSH, Increase to High	8 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	T4, Free, Decrease to Low	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	T4, Free, Change to Normal or No Change	23 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters	T4, Free, Increase to High	1 Participants

Secondary

Part 2 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results

Urine samples were collected to assess urine glucose, protein, occult blood and ketones using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for uranalysis parameters were recorded as no change/decreased and any increase. Data for worst-case post baseline are presented.

Time frame: Baseline (Day 1) and up to approximately 178 weeks

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Glucose, No Change/Decreased	25 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Glucose, Any Increase	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Ketones, No Change/Decreased	21 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Ketones, Any Increase	5 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Occult Blood, No Change/Decreased	15 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Occult Blood, Any Increase	9 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Protein, No Change/Decreased	20 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results	Protein, Any Increase	6 Participants

Secondary

Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters

Blood samples were collected for the analysis of following hematology parameters: hemoglobin, White blood cell (WBC) count, lymphocytes, neutrophils and platelet. The laboratory parameters were graded according to NCI-CTCAE version 4.03. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Any worst case post baseline increase in grade along with any increase to a maximum grade of 3 and a maximum grade of 4 are presented.

Time frame: Baseline (Day 1) and up to approximately 178 weeks

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Anemia, Increase to Grade 3	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Anemia, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Hemoglobin increased, Any Grade Increase	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Hemoglobin increased, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Hemoglobin increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Lymphocyte count decreased, Increase to Grade 4	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Lymphocyte count increased, Any Grade Increase	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Platelet count decreased, Increase to Grade 3	7 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Anemia, Any Grade Increase	10 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Leukocytosis, Any Grade Increase	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Leukocytosis, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Leukocytosis, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	WBC decreased, Any Grade Increase	11 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	WBC decreased, Increase to Grade 3	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	WBC decreased, Increase to Grade 4	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Lymphocyte count decreased, Any Grade Increase	14 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Lymphocyte count decreased, Increase to Grade 3	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Lymphocyte count increased, Increase to Grade 3	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Lymphocyte count increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Neutrophil count decreased, Any Grade Increase	9 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Neutrophil count decreased, Increase to Grade 3	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Neutrophil count decreased, Increase to Grade 4	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Platelet count decreased, Any Grade Increase	18 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Platelet count decreased, Increase to Grade 4	4 Participants

Secondary

Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters

Blood samples were collected for the analysis of clinical chemistry parameters: glucose, alanine aminotransferase (ALT), albumin, alkaline phosphatase, aspartate aminotransferase (AST), blood bilirubin, calcium, creatine kinase (CPK), creatinine, gamma glutamyl transferase (GGT), magnesium, phosphate potassium and sodium. Laboratory parameters were graded according to NCI-CTCAE version 4.03. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Any worst case post baseline increase in grade along with any increase to a maximum grade of 3 and a maximum grade of 4 are presented.

Time frame: Baseline (Day 1) and up to approximately 178 weeks

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypoalbuminemia, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Alkaline phosphatase increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypercalcemia, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypercalcemia, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypocalcemia, Any Grade Increase	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	CPK increased, Any Grade Increase	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	CPK increased, Increase to Grade 3	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Creatinine increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypermagnesemia, Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypermagnesemia, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypokalemia, Any Grade Increase	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hyponatremia, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hyperglycemia, Any Grade Increase	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hyperglycemia, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hyperglycemia, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypoglycemia, Any Grade Increase	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypoglycemia, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypoglycemia, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	ALT increased, Any Grade Increase	5 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	ALT increased, Increase to Grade 3	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	ALT increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypoalbuminemia, Any Grade Increase	9 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypoalbuminemia, Increase to Grade 3	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Alkaline phosphatase increased, Any Grade Increase	9 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Alkaline phosphatase increased, Increase to Grade 3	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	AST increased, Any Grade Increase	20 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	AST increased, Increase to Grade 3	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	AST increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Blood bilirubin increased, Any Grade Increase	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Blood bilirubin increased, Increase to Grade 3	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Blood bilirubin increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypercalcemia, Any Grade Increase	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypocalcemia, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypocalcemia, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	CPK increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Creatinine increased, Any Grade Increase	7 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Creatinine increased, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	GGT increased, Any Grade Increase	10 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	GGT increased, Increase to Grade 3	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	GGT increased, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypermagnesemia, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypomagnesemia, Any Grade Increase	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypomagnesemia, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypomagnesemia, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypophosphatemia, Any Grade Increase	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypophosphatemia, Increase to Grade 3	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypophosphatemia, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hyperkalemia, Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hyperkalemia, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hyperkalemia, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypokalemia, Increase to Grade 3	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypokalemia, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypernatremia, Any Grade Increase	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypernatremia, Increase to Grade 3	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hypernatremia, Increase to Grade 4	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hyponatremia, Any Grade Increase	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters	Hyponatremia, Increase to Grade 3	1 Participants

Secondary

Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: DBP and SBP

DBP and SBP were measured after resting for at least 5 minutes in a supine or semi-recumbent position. They were graded according to NCI-CTCAE version 4.0. For SBP: Grade 0 (\<=120 millimeter of mercury \[mmHg\]), Grade 1 (121-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (\>=160 mmHg). For DBP: Grade 0 (\<=80 mmHg), Grade 1 (81-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (\>=100 mmHg). Higher grade indicates greater severity. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. An increase is defined as an increase in grade relative to Baseline grade. Data for worst-case post Baseline with any grade increase and a maximum post-baseline grade increase to Grade 3 from their baseline grade are presented.

Time frame: Baseline (Day 1) and up to approximately 178 weeks

Population: All Treated Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: DBP and SBP	SBP, Increase to Grade 3	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: DBP and SBP	DBP, Any Grade Increase	20 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: DBP and SBP	DBP, Increase to Grade 2	12 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: DBP and SBP	DBP, Increase to Grade 3	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: DBP and SBP	SBP, Any Grade Increase	24 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: DBP and SBP	SBP, Increase to Grade 2	16 Participants

Secondary

Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations

Participants with worst-case shift from baseline in corneal examination: corneal ulcer, epithelial microcystic edema, subepithelial haze, corneal neovascularization and microcysts without edema, by right eye (R), left eye (L) and worse eye (W) are presented as yes (Y), no (N) and missing (M). Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.

Time frame: Baseline (Day 1) and up to approximately 178 weeks

Population: All Treated Population

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator left eye	Baseline N, Post-Baseline N	23 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator right eye	Baseline N, Post-Baseline N	21 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator right eye	Baseline N, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator right eye	Baseline N, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator right eye	Baseline Y, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator right eye	Baseline Missing, Post-Baseline N	5 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator right eye	Baseline Missing, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator right eye	Baseline Missing, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator worst eye	Baseline N, Post-Baseline N	23 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator worst eye	Baseline Y, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator worst eye	Baseline Y, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator right eye	Baseline N, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator right eye	Baseline Y, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator left eye	Baseline N, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator left eye	Baseline Y, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator left eye	Baseline Y, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator left eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator left eye	Baseline Missing, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator left eye	Baseline Missing, Post-Baseline Y	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator left eye	Baseline Missing, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator right eye	Baseline Y, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator right eye	Baseline Y, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator right eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator right eye	Baseline Missing, Post-Baseline N	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator worst eye	Baseline N, Post-Baseline Y	15 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator worst eye	Baseline N, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator worst eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator worst eye	Baseline Missing, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator left eye	Baseline N, Post-Baseline N	22 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator left eye	Baseline N, Post-Baseline Y	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator left eye	Baseline Y, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator left eye	Baseline Y, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator left eye	Baseline Missing, Post-Baseline Y	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator right eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator right eye	Baseline Missing, Post-Baseline N	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator right eye	Baseline Missing, Post-Baseline Y	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator right eye	Baseline Missing, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator worst eye	Baseline N, Post-Baseline N	21 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator worst eye	Baseline N, Post-Baseline Y	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator worst eye	Baseline N, Post-Baseline Missing	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator worst eye	Baseline Y, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator right eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator right eye	Baseline Missing, Post-Baseline N	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator right eye	Baseline Missing, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator right eye	Baseline Missing, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator worst eye	Baseline N, Post-Baseline N	17 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator worst eye	Baseline N, Post-Baseline Y	9 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator worst eye	Baseline Y, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator worst eye	Baseline Y, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator worst eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator worst eye	Baseline Missing, Post-Baseline N	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator worst eye	Baseline Missing, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator worst eye	Baseline Missing, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator left eye	Baseline N, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator left eye	Baseline N, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator left eye	Baseline Y, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator left eye	Baseline Y, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator left eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator left eye	Baseline Missing, Post-Baseline N	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator left eye	Baseline Missing, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator left eye	Baseline Missing, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator right eye	Baseline Y, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator right eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator worst eye	Baseline N, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator worst eye	Baseline N, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator worst eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator worst eye	Baseline Missing, Post-Baseline N	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator worst eye	Baseline Missing, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal ulcer indicator worst eye	Baseline Missing, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator left eye	Baseline N, Post-Baseline N	17 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator left eye	Baseline N, Post-Baseline Y	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator left eye	Baseline N, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator left eye	Baseline Y, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator left eye	Baseline Y, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator left eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator left eye	Baseline Missing, Post-Baseline N	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator left eye	Baseline Missing, Post-Baseline Y	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator left eye	Baseline Missing, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator right eye	Baseline N, Post-Baseline N	16 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator right eye	Baseline N, Post-Baseline Y	5 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator right eye	Baseline Y, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator right eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator right eye	Baseline Missing, Post-Baseline N	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator right eye	Baseline Missing, Post-Baseline Y	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator right eye	Baseline Missing, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator worst eye	Baseline N, Post-Baseline N	17 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator worst eye	Baseline N, Post-Baseline Y	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator worst eye	Baseline N, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator worst eye	Baseline Y, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator worst eye	Baseline Y, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator worst eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator worst eye	Baseline Missing, Post-Baseline N	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator worst eye	Baseline Missing, Post-Baseline Y	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Epithelial microcystic edema indicator worst eye	Baseline Missing, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator left eye	Baseline N, Post-Baseline N	8 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator left eye	Baseline N, Post-Baseline Y	15 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator right eye	Baseline N, Post-Baseline N	7 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator right eye	Baseline N, Post-Baseline Y	14 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator right eye	Baseline N, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator right eye	Baseline Missing, Post-Baseline Y	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator right eye	Baseline Missing, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator worst eye	Baseline N, Post-Baseline N	8 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator worst eye	Baseline Y, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator worst eye	Baseline Y, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator worst eye	Baseline Missing, Post-Baseline Y	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Microcysts without edema indicator worst eye	Baseline Missing, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator left eye	Baseline N, Post-Baseline Missing	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator left eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator left eye	Baseline Missing, Post-Baseline N	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator left eye	Baseline Missing, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator right eye	Baseline N, Post-Baseline N	20 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator right eye	Baseline N, Post-Baseline Y	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator right eye	Baseline N, Post-Baseline Missing	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator right eye	Baseline Y, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator right eye	Baseline Y, Post-Baseline Y	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator worst eye	Baseline Y, Post-Baseline Y	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator worst eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator worst eye	Baseline Missing, Post-Baseline N	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator worst eye	Baseline Missing, Post-Baseline Y	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Corneal neovascularization indicator worst eye	Baseline Missing, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator left eye	Baseline N, Post-Baseline N	16 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator left eye	Baseline N, Post-Baseline Y	9 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator left eye	Baseline N, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator left eye	Baseline Y, Post-Baseline N	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator left eye	Baseline Y, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator left eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator left eye	Baseline Missing, Post-Baseline N	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator left eye	Baseline Missing, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator left eye	Baseline Missing, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator right eye	Baseline N, Post-Baseline N	16 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator right eye	Baseline N, Post-Baseline Y	8 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator right eye	Baseline N, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator right eye	Baseline Y, Post-Baseline N	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator right eye	Baseline Y, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations	Subepithelial haze indicator worst eye	Baseline N, Post-Baseline Missing	1 Participants

Secondary

Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations

Participants with worst-case shift from baseline in corneal examination which included: clear, pseudophakia, nuclear sclerosis, cortical cataract and posterior subcapsular cataract by right eye, left eye and worse eye are presented as yes (Y), no (N) and missing. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.

Time frame: Baseline (Day 1) and up to approximately 178 weeks

Population: All Treated Population

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Right eye	Baseline Y, Post-Baseline Missing	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Right eye	Baseline Missing, Post-Baseline N	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Right eye	Baseline Missing, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Worse eye	Baseline N, Post-Baseline N	7 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Worse eye	Baseline N, Post-Baseline Y	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Worse eye	Baseline N, Post-Baseline N=Missing	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Worse eye	Baseline Y, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Worse eye	Baseline Missing, Post-Baseline N	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Worse eye	Baseline Missing, Post-Baseline Y	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Worse eye	Baseline Missing, Post-Baseline Missing	10 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Left eye	Baseline N, Post-Baseline Y	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Right eye	Baseline N, Post-Baseline Y	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Right eye	Baseline N, Post-Baseline N=Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Right eye	Baseline Y, Post-Baseline N	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Left eye	Baseline Y, Post-Baseline Y	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Left eye	Baseline Y, Post-Baseline Missing	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Right eye	Baseline Missing, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Worse eye	Baseline Y, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, Left eye	Baseline N, Post-Baseline N	12 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, Left eye	Baseline N, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, Left eye	Baseline N, Post-Baseline N=Missing	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, Left eye	Baseline Y, Post-Baseline N	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, Left eye	Baseline Y, Post-Baseline Y	10 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, Left eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, Left eye	Baseline Missing, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, Left eye	Baseline Missing, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, Left eye	Baseline Missing, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, Right eye	Baseline N, Post-Baseline N	12 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, Right eye	Baseline N, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, Right eye	Baseline N, Post-Baseline N=Missing	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, Right eye	Baseline Y, Post-Baseline N	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, Right eye	Baseline Y, Post-Baseline Y	10 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, Right eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, Right eye	Baseline Missing, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, Right eye	Baseline Missing, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, Right eye	Baseline Missing, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, worse eye	Baseline N, Post-Baseline N	12 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, worse eye	Baseline N, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, worse eye	Baseline N, Post-Baseline N=Missing	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, worse eye	Baseline Y, Post-Baseline N	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, worse eye	Baseline Y, Post-Baseline Y	10 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, worse eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, worse eye	Baseline Missing, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, worse eye	Baseline Missing, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Clear Indicator, worse eye	Baseline Missing, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Left eye	Baseline N, Post-Baseline N	7 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Left eye	Baseline N, Post-Baseline Y	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Left eye	Baseline N, Post-Baseline N=Missing	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Left eye	Baseline Y, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Left eye	Baseline Y, Post-Baseline Y	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Left eye	Baseline Y, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Left eye	Baseline Missing, Post-Baseline N	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Left eye	Baseline Missing, Post-Baseline Y	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Left eye	Baseline Missing, Post-Baseline Missing	10 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Right eye	Baseline N, Post-Baseline N	7 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Right eye	Baseline N, Post-Baseline Y	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Right eye	Baseline N, Post-Baseline N=Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Right eye	Baseline Y, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Right eye	Baseline Y, Post-Baseline Y	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Right eye	Baseline Missing, Post-Baseline Missing	10 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Worse eye	Baseline Y, Post-Baseline Y	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Cortical Cataract Indicator, Worse eye	Baseline Y, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Left eye	Baseline N, Post-Baseline N	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Left eye	Baseline N, Post-Baseline N=Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Left eye	Baseline Y, Post-Baseline N	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Left eye	Baseline Y, Post-Baseline Y	8 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Left eye	Baseline Y, Post-Baseline Missing	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Left eye	Baseline Missing, Post-Baseline N	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Left eye	Baseline Missing, Post-Baseline Y	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Left eye	Baseline Missing, Post-Baseline Missing	10 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Right eye	Baseline N, Post-Baseline N	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Right eye	Baseline Y, Post-Baseline Y	8 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Right eye	Baseline Y, Post-Baseline Missing	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Right eye	Baseline Missing, Post-Baseline N	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Right eye	Baseline Missing, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Right eye	Baseline Missing, Post-Baseline Missing	10 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Worse eye	Baseline N, Post-Baseline N	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Worse eye	Baseline N, Post-Baseline Y	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Worse eye	Baseline N, Post-Baseline N=Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Worse eye	Baseline Y, Post-Baseline N	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Worse eye	Baseline Y, Post-Baseline Y	8 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Worse eye	Baseline Y, Post-Baseline Missing	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Worse eye	Baseline Missing, Post-Baseline N	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Worse eye	Baseline Missing, Post-Baseline Y	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Nuclear Sclerosis, Worse eye	Baseline Missing, Post-Baseline Missing	10 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Left eye	Baseline N, Post-Baseline N	7 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Left eye	Baseline N, Post-Baseline Y	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Left eye	Baseline N, Post-Baseline N=Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Left eye	Baseline Y, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Left eye	Baseline Missing, Post-Baseline N	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Left eye	Baseline Missing, Post-Baseline Y	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Left eye	Baseline Missing, Post-Baseline Missing	10 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Right eye	Baseline N, Post-Baseline N	7 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Right eye	Baseline N, Post-Baseline Y	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Right eye	Baseline N, Post-Baseline N=Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Right eye	Baseline Y, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Left eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Right eye	Baseline Y, Post-Baseline Y	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Right eye	Baseline Y, Post-Baseline Missing	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Right eye	Baseline Missing, Post-Baseline N	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Right eye	Baseline Missing, Post-Baseline Y	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Right eye	Baseline Missing, Post-Baseline Missing	10 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Worse eye	Baseline N, Post-Baseline N	6 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Worse eye	Baseline N, Post-Baseline Y	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Worse eye	Baseline N, Post-Baseline N=Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Worse eye	Baseline Y, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Worse eye	Baseline Y, Post-Baseline Y	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Worse eye	Baseline Y, Post-Baseline Missing	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Worse eye	Baseline Missing, Post-Baseline N	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Worse eye	Baseline Missing, Post-Baseline Y	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Posterior Subcapsular Cataract, Worse eye	Baseline Missing, Post-Baseline Missing	10 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Left eye	Baseline N, Post-Baseline N	11 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Left eye	Baseline N, Post-Baseline Y	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Left eye	Baseline N, Post-Baseline N=Missing	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Left eye	Baseline Y, Post-Baseline N	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Left eye	Baseline Y, Post-Baseline Y	10 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Left eye	Baseline Missing, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Left eye	Baseline Missing, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Left eye	Baseline Missing, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Right eye	Baseline N, Post-Baseline N	12 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Right eye	Baseline N, Post-Baseline Y	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Right eye	Baseline N, Post-Baseline N=Missing	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Right eye	Baseline Y, Post-Baseline N	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Right eye	Baseline Y, Post-Baseline Y	10 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Right eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Right eye	Baseline Missing, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Right eye	Baseline Missing, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Worse eye	Baseline N, Post-Baseline N	11 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Worse eye	Baseline N, Post-Baseline Y	4 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Worse eye	Baseline N, Post-Baseline N=Missing	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Worse eye	Baseline Y, Post-Baseline Y	10 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Worse eye	Baseline Y, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Worse eye	Baseline Missing, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Worse eye	Baseline Missing, Post-Baseline Y	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations	Pseudophakia, Worse eye	Baseline Missing, Post-Baseline Missing	0 Participants

Secondary

Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam

Participants with worst-case shift from baseline in corneal epithelium defects by right eye, left eye and worse eye are presented as normal (N), abnormal (AN) and missing. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.

Time frame: Baseline (Day 1) and up to approximately 178 weeks

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam	Left Eye	Baseline AN, Post-Baseline AN	8 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam	Right Eye	Baseline N, Post-Baseline N	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam	Right Eye	Baseline N, Post-Baseline AN	16 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam	Right Eye	Baseline AN, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam	Right Eye	Baseline AN, Post-Baseline AN	8 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam	Right Eye	Baseline N, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam	Right Eye	Baseline AN, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam	Left Eye	Baseline N, Post-Baseline N	2 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam	Left Eye	Baseline N, Post-Baseline AN	16 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam	Left Eye	Baseline AN, Post-Baseline N	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam	Left Eye	Baseline N, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam	Left Eye	Baseline AN, Post-Baseline Missing	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam	Worse Eye	Baseline N, Post-Baseline N	3 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam	Worse Eye	Baseline N, Post-Baseline AN	17 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam	Worse Eye	Baseline AN, Post-Baseline N	0 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam	Worse Eye	Baseline AN, Post-Baseline AN	7 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam	Worse Eye	Baseline N, Post-Baseline Missing	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam	Worse Eye	Baseline AN, Post-Baseline Missing	0 Participants

Secondary

Part 2 - Outcome of First Occurrence of Worsening Eye in BCVA Score

The onset of any visual acuity event (change from baseline in logMAR score \>= 0.3 in either eye) was considered resolved if the change from baseline in logMAR score was less than 0.3 in both eyes. Participants with resolved and not resolved outcome of the worsening eye were presented.

Time frame: Up to approximately 178 weeks

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Outcome of First Occurrence of Worsening Eye in BCVA Score	Not resolved	1 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Outcome of First Occurrence of Worsening Eye in BCVA Score	Resolved prior to end of treatment exposure	7 Participants
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Outcome of First Occurrence of Worsening Eye in BCVA Score	Resolved post end of treatment exposure	2 Participants

Secondary

Part 2 - Overall Survival

Overall Survival was defined as the time from first dose until death due to any cause.

Time frame: Up to approximately 178 weeks

Population: All Treated Population

Arm	Measure	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Overall Survival	NA Months

Secondary

Part 2 - Percentage of Participants With Clinical Benefit Rate

Clinical benefit rate was defined as the percentage of participants with a confirmed minimal response (MR) or better according to the IMWG Response Criteria. MR is \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%.

Time frame: Up to approximately 178 weeks

Population: All Treated Population

Arm	Measure	Value (NUMBER)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Percentage of Participants With Clinical Benefit Rate	43 Percentage of Participants

Secondary

Part 2 - Progression-free Survival

Progression-free survival was defined as the time from first dose until the earliest date of PD per IMWG response criteria, or death due to any cause. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h).

Time frame: Up to approximately 178 weeks

Population: All Treated Population

Arm	Measure	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Progression-free Survival	2.5 Months

Secondary

Part 2 - Time Taken for the Onset of First Occurrence of Worsening in BCVA Score

The time for the onset of any visual acuity event (change from baseline logMAR score \>= 0.3 in either eye) was calculated.

Time frame: Up to approximately 178 weeks

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Time Taken for the Onset of First Occurrence of Worsening in BCVA Score	78.0 Days

Secondary

Part 2 - Time to Best Response

Time to best response was defined as the time between the date of first dose and the first best documented response (PR or better) among participants who achieved a confirmed response of PR or better.

Time frame: Up to approximately 178 weeks

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Time to Best Response	1.7 Months

Secondary

Part 2 - Time to Disease Progression

Time to disease progression was defined as the time from first dose until the earliest date of PD per IMWG response criteria, or death due to PD. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h).

Time frame: Up to approximately 178 weeks

Population: All Treated Population

Arm	Measure	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Time to Disease Progression	2.5 Months

Secondary

Part 2 - Time to Response

Time to response (TTR) was defined as the time between the date of first dose and the first documented evidence of response (PR or better) among participants who achieved a confirmed response of PR or better.

Time frame: Up to approximately 178 weeks

Population: All Treated Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Time to Response	0.7 Months

Secondary

Part 2 - Titers of ADAs Against Belantamab Mafodotin

Time frame: Baseline (Day 1) and up to approximately 178 weeks

Population: All Treated Population. There were no participants with positive ADA results. Hence the titer (concentration) of ADA was not collected.

Secondary

Part 2 - Tlast for Belantamab Mafodotin After First Dose

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Due to bioanalytical issues, PK data were not collected and analyzed for belantamab mafodotin. Therefore, this PK parameter was not reported in this study

Secondary

Part 2 - Tlast for Cys-mcMMAF After First Dose

Time frame: Pre-dose, EOI, 2, 4, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population

Arm	Measure	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Tlast for Cys-mcMMAF After First Dose	167.510 Hour

Secondary

Part 2 - Tlast for Total mAb After First Dose

Time frame: Pre-dose, EOI, 2, 4, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population

Arm	Measure	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Tlast for Total mAb After First Dose	503.140 Hour

Secondary

Part 2 - Tmax for Belantamab Mafodotin After First Dose

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Due to bioanalytical issues, PK data were not collected and analyzed for belantamab mafodotin. Therefore, this PK parameter was not reported in this study

Secondary

Part 2 - Tmax for Cys-mcMMAF After First Dose

Time frame: Pre-dose, EOI, 2, 4, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Tmax for Cys-mcMMAF After First Dose	23.580 Hour

Secondary

Part 2 - Tmax for Pembrolizumab After First Dose

Time frame: Pre-dose, EOI, 2, 4, 9, and 24 h post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Pembrolizumab data were not collected and analyzed. Therefore, this PK parameter was not reported in this study.

Secondary

Part 2 - Tmax for Total mAb After First Dose

Time frame: Pre-dose, EOI, 2, 4, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1

Population: Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.

Arm	Measure	Value (MEDIAN)
Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation	Part 2 - Tmax for Total mAb After First Dose	0.945 Hour

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026

Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Masking description

Intervention model description

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Part 1 - Changes From Baseline in Urine Potential of Hydrogen (pH)

Part 1 - Changes From Baseline in Urine Specific Gravity

Part 1 - Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Part 1 - Number of Participants With Dose Limiting Toxicities (DLTs)

Part 1 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature

Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters

Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters

Part 1 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results

Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters

Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters

Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)

Part 2 - Percentage of Participants With Overall Response Rate (ORR)

Part 1 - Area Under Plasma Concentration-time Curve (AUC) From Time 0 to End of the Dosing Interval [AUC (0-tau)] for Belantamab Mafodotin After First Dose

Part 1 - AUC (0-tau) for Pembrolizumab After First Dose

Part 1 - AUC (0-tau) for Total mAb After First Dose

Part 1 - AUC From Time 0 to 168 h After Dosing [AUC (0-168h)] for Cys-mcMMAF After First Dose

Part 1 - C-EOI for Cys-mcMMAF After First Dose

Part 1 - C-EOI for Total mAb

Part 1 - Cmax for Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF) After First Dose

Part 1 - Cmax for Pembrolizumab After First Dose

Part 1 - Cmax for Total Monoclonal Antibody (mAb) After First Dose

Part 1 - Ctrough for Total mAb

Part 1 - End of Infusion Concentration (C-EOI) for Belantamab Mafodotin

Part 1 - Last Time Point Where the Concentration is Above the Limit of Quantification (Tlast) for Belantamab Mafodotin After First Dose

Part 1 - Last Time Point Where the Concentration is Above the Limit of Quantification (Tlast) for Total mAb After First Dose

Part 1 - Maximum Concentration (Cmax) for Belantamab Mafodotin After First Dose

Part 1 - Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin

Part 1 - Percentage of Participants With Overall Response Rate (ORR)

Part 1 - Time of Cmax (Tmax) for Belantamab Mafodotin After First Dose

Part 1 - Titers of ADAs Against Belantamab Mafodotin

Part 1 - Tlast for Cys-mcMMAF After First Dose

Part 1 - Tmax for Cys-mcMMAF After First Dose

Part 1 - Tmax for Pembrolizumab After First Dose

Part 1 - Tmax for Total mAb After First Dose

Part 1 - Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin

Part 2 - AUC (0-168 h) for Cys-mcMMAF After First Dose

Part 2 - AUC (0-tau) for Belantamab Mafodotin After First Dose

Part 2 - AUC (0-tau) for Pembrolizumab After First Dose

Part 2 - AUC (0-tau) for Total mAb After First Dose

Part 2 - C-EOI for Belantamab Mafodotin

Part 2 - C-EOI for Cys-mcMMAF After First Dose

Part 2 - C-EOI for Total mAb

Part 2 - Changes From Baseline in Urine pH

Part 2 - Changes From Baseline in Urine Specific Gravity

Part 2 - Cmax for Belantamab Mafodotin After First Dose

Part 2 - Cmax for Cys-mcMMAF After First Dose

Part 2 - Cmax for Pembrolizumab After First Dose

Part 2 - Cmax for Total mAb After First Dose

Part 2 - Ctrough for Belantamab Mafodotin

Part 2 - Ctrough for Total mAb

Part 2 - Duration of First Occurrence of Worsening in BCVA Score

Part 2 - Duration of Resolution Post-treatment Exposure of Worsening in BCVA Score

Part 2 - Duration of Response

Part 2 - Number of Participants According to the Number of Definite Events of Worsening of Vision

Part 2 - Number of Participants With AEs and SAEs